Patent · US Active

Aminothiol reduction of ischemia-reperfusion-induced cell death

US11690813B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignee

OBVIA PHARMACEUTICALS LTD · US

Inventors

William E. Fahl · 安丰镇, CN
Ningfeng Li · Shanghai, CN

Key dates

Filing date	Jan 4, 2019
Grant date	Jul 4, 2023
Priority date	—
Expiry date	May 27, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Members of the PrC-210 family of aminothiols, including PrC-211 and PrC-252, are shown to be highly effective in reducing ischemia-reperfusion injury in two preclinical models, including kidney transplant and myocardial infarct. Compositions and methods employing members of the PrC-210 family of aminothiols are disclosed for suppressing ischemia-reperfusion-induced cell and organ toxicities in a number of settings, significantly including organ transplant and myocardial infarct.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.